Form 4: ADC Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations

ADC Therapeutics' Chief Medical Officer, Mohamed Zaki, sold 37,112 common shares to cover tax obligations related to vesting restricted share units.

Summary

• Mohamed Zaki, the Chief Medical Officer of ADC Therapeutics, sold 37,112 common shares on December 6, 2024.
• The sale was executed at a price of $3.13 per share.
• This transaction was to cover tax withholding obligations related to the vesting of previously granted restricted share units.
• Following the transaction, Mr. Zaki directly owns 232,888 common shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Similar transactions are common among executives in publicly traded companies, particularly in the biotech sector where stock-based compensation is a significant part of executive pay.
• The sale of shares to cover tax obligations is a standard practice and does not necessarily indicate a change in the executive's outlook on the company's future.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

ADC Therapeutics, Mohamed Zaki, Chief Medical Officer, share sale, tax obligations, restricted share units, insider trading, ADCT